Uno studio per valutare Venetoclax potenziato con cobicistat in combinazione con azacitidina in pazienti adulti con leucemia mieloide acuta di nuova diagnosi (HO171)
Uno studio di fase II a braccio singolo per valutare Venetoclax potenziato con cobicistat in combinazione con azacitidina (sc) in pazienti adulti con leucemia mieloide acuta (LMA) di nuova diagnosi che non sono considerati candidati per regimi di trattamento intensivo
The treatment of older unfit patients with acute myeloid leukemia (AML) is challenging. The hypomethylating agents (HMA) azacitidine and decitabine have relatively mild side effects and have proven to be feasible for the treatment of older patients and patients with co-morbidities. Currently, venetoclax added to an HMA agent is the new standard of treatment. Since this new standard comes with a substantial societal financial burden, there is a rational to optimize the venetoclax dosing schedule. The CYP3A4 inhibitor cobicistat (COBI) can be used to increase venetoclax exposure, thereby allowing to reduce the dose of venetoclax and thus costs substantially.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Fase
Fase
- Fase 2
Contatti e Sedi
Contatto studio
Contatto studio
- Nome: Gerwin Huls, prof
- Numero di telefono: +3150 361 2354
- Email: g.huls@umcg.nl
Luoghi di studio
-
-
-
's-Hertogenbosch, Olanda
- Reclutamento
- NL-Den Bosch-JBZ
-
Contatto:
- A.H.E. Herbers, Dr.
-
Amersfoort, Olanda
- Reclutamento
- NL-Amersfoort-MEANDERMC
-
Contatto:
- M.F. Corsten, Dr.
-
Amsterdam, Olanda
- Reclutamento
- NL-Amsterdam-OLVG
-
Contatto:
- H. Mooij, Dr.
-
Amsterdam, Olanda
- Reclutamento
- NL-Amsterdam-AUMC
-
Contatto:
- C. Alhan, Dr.
-
Arnhem, Olanda
- Reclutamento
- NL-Arnhem-RIJNSTATE
-
Contatto:
- M.L.H. Cuijpers, Dr.
-
Breda, Olanda
- Reclutamento
- NL-Breda-AMPHIA
-
Contatto:
- R.B. Fiets, Dr.
-
Dordrecht, Olanda
- Reclutamento
- NL-Dordrecht-ASZ
-
Contatto:
- P.E. Westerweel, Dr.
-
Eindhoven, Olanda
- Reclutamento
- NL-Eindhoven-MAXIMAMC
-
Contatto:
- L.W. Tick, Dr.
-
Eindhoven, Olanda
- Reclutamento
- NL-Eindhoven-CATHARINA
-
Contatto:
- M.J. Cruijsen, Dr.
-
Enschede, Olanda
- Reclutamento
- NL-Enschede-MST
-
Contatto:
- T.J.F. Snijders, Dr.
-
Groningen, Olanda
- Reclutamento
- NL-Groningen-UMCG
-
Contatto:
- G.A. Huls, Prof. dr.
-
Leeuwarden, Olanda
- Reclutamento
- NL-Leeuwarden-MCL
-
Contatto:
- B. Franken, Dr.
-
Leiden, Olanda
- Reclutamento
- NL-Leiden-LUMC
-
Contatto:
- P.A. von dem Borne, Dr.
-
Maastricht, Olanda
- Reclutamento
- NL-Maastricht-MUMC
-
Contatto:
- C.H.M.J. van Elssen, Dr.
-
Nieuwegein, Olanda
- Reclutamento
- NL-Nieuwegein-ANTONIUS
-
Contatto:
- O. de Weerdt, Dr.
-
Nijmegen, Olanda
- Reclutamento
- NL-Nijmegen-RADBOUDUMC
-
Contatto:
- N.A. de Jonge, Dr.
-
Nijmegen, Olanda
- Reclutamento
- NL-Nijmegen-CWZ
-
Contatto:
- S. de Jonge, Dr.
-
The Hague, Olanda
- Reclutamento
- NL-Den Haag-HAGA
-
Contatto:
- D. van Lammeren, Dr.
-
Zwolle, Olanda
- Reclutamento
- NL-Zwolle-ISALA
-
Contatto:
- T.T. de Waal, Dr.
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
In order to be eligible to participate in this study, a patient must meet all of the following criteria:
-
Patients with: a diagnosis of AML and related precursor neoplasms according to ICC-2022 classification (excluding acute promyelocytic leukaemia) (appendix A). Patients may have had previous treatment with erythropoiesis stimulating agents (ESA) for an antecedent phase of MDS. ESAs must be stopped at least two weeks before registration.
-
Patients 18 years and older who are considered not fit for intensive chemotherapy or who decline the option of intensive chemotherapy.
-
WHO performance status 0, 1 or 2 (appendix E).
-
Leukocytes < 30 x109/L
-
Adequate renal and hepatic functions unless clearly disease related as indicated by the following laboratory values:
- Adequate renal function as demonstrated by a creatinine clearance ≥ 30 mL/min; calculated by the Cockcroft Gault formula or measured by 24 hours urine collection.
- Serum bilirubin ≤ 3 x upper limit of normal (ULN), unless considered AML-related or due to Gilbert's syndrome.
- Alanine transaminase (ALT) ≤ 3 x ULN, unless considered AML-related.
-
Male subjects who are sexually active, must agree, from Study Day 1 until at least 90 days after the last dose of study drug, to practice the protocol specified contraception. Male subjects must agree to refrain from sperm donation from initial study drug administration through at least 90 days after the last dose of study drug.
-
Female subjects must be either postmenopausal defined as: Age >55 years with no menses for ≥12 months, without an alternative medical cause. OR willing and able to use adequate contraception during and until 180 days after the last protocol treatment.
-
Written informed consent.
-
Patient is capable of giving informed consent.
-
Patient agrees not to participate in another interventional study while on treatment without approval of the (co-) Principal Investigator.
Exclusion Criteria:
A patient who meets any of the following criteria cannot be included in this study:
-
Acute promyelocytic leukemia.
-
Myelodysplastic syndrome (MDS).
-
Patients previously treated for AML or MDS (any anti-leukemic therapy including investigational agents; excluding: 1) erythropoiesis stimulating agents (ESAs); 2) hydroxyurea ((previous treatment with hydroxyurea is allowed for the control of peripheral leukemic blasts in patients with leukocytosis).
-
Diagnosis of any previous or concomitant malignancy is an exclusion criterion:
- except when the patient successfully completed treatment (chemotherapy and/or surgery and/or radiotherapy) with curative intent for this malignancy at least 24 months prior to registration;
- except for basal and squamous cell carcinoma of the skin or in situ carcinoma of the cervix.
-
Blast crisis of chronic myeloid leukemia.
-
Concurrent severe and/or uncontrolled medical condition (e.g. uncontrolled diabetes, infection, hypertension, pulmonary disease etc.).
-
Cardiac dysfunction as defined by:
- Myocardial infarction within the last 3 months of study entry, or
- Reduced left ventricular function with an ejection fraction < 40% as measured by MUGA scan or echocardiogram, or
- Unstable angina or New York Heart Association (NYHA) grade IV congestive heart failure (see Appendix G), or
- Unstable cardiac arrhythmias.
-
History of stroke or intracranial haemorrhage within 6 months prior to registration.
-
Symptomatic central nervous system (CNS) leukemia (NO routinely lumbar puncture required to investigate CNS involvement).
-
History of non-compliance to medical regimens or considered unreliable with respect to compliance.
-
Senile dementia, mental impairment or any other psychiatric disorder that prohibits the patient from understanding and giving informed consent.
-
Current concomitant chemotherapy, radiation therapy, or immunotherapy; other than hydroxyurea.
-
Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule.
-
Unreplaceable use of strong inhibitors or inducers of CYP3A or CYP3A/p-GP substrates with a narrow therapeutic window (e.g. cobicistat or ritonavir for HIV treatment). Please check with Appendix I.
-
Intolerability, contra-indication or allergy to one of the study drugs.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: N / A
- Modello interventistico: Assegnazione sequenziale
- Mascheramento: Nessuno (etichetta aperta)
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: single arm arm extension phase
prior to the extention phase, there is a run-in phase with (n= 20 patients of 142 total) with the same study scheme, except that cobicistat is added from cycle 2 onwards to the treatment instead of during cycle 1 |
during run-in and extention phase: from Cycle 1 until relapse during run-in and extention phase: from Cycle 1 until relapse during run-in phase: from cycle 2 until relapse during extension phase: from cycle 1 until relapse |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Pharmacokinetic equivalence of cobicistat boosted venetoclax and unboosted venetoclax (PK cycle 1 vs PK cycle 2).venetoclax and unboosted venetoclax (PK cycle 1 vs PK cycle 2).
Lasso di tempo: 6-8 months
|
run-in phase |
6-8 months
|
|
Overall survival (OS).
Lasso di tempo: 48 months
|
extension phase |
48 months
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Venetoclax and cobicistat CL, Cmax, Tmax, Cmin and AUC0-24.
Lasso di tempo: 6-8 months
|
run-in phase |
6-8 months
|
|
Complete remission (CR) rate defined as CR as best response during or at completion of the treatment, as determined by the Investigator, based on the European LeukemiaNet (ELN2022) recommended response criteria (see Appendix B).
Lasso di tempo: 48 months
|
extension phase |
48 months
|
|
CR with incomplete hematologic recovery (CRi) rate, based on the European LeukemiaNet (ELN2022) recommended response criteria (see Appendix B).
Lasso di tempo: 48 months
|
extension phase |
48 months
|
|
CR and CR with incomplete hematologic recovery (CRi) rate, based on the European LeukemiaNet (ELN2022) recommended response criteria (see Appendix B).
Lasso di tempo: 48 months
|
extension phase |
48 months
|
|
CR with partial hematologic recovery (CRh) rate, based on ELN 2022 recommendations.
Lasso di tempo: 48 months
|
extension phase |
48 months
|
|
CR and CR with partial hematologic recovery (CRh) rate, based on ELN 2022 recommendations.
Lasso di tempo: 48 months
|
extension phase |
48 months
|
|
CR or CR/CRi or CR/CRh without minimal residual disease (flow and or molecular) (CRMRD- or CR/CRiMRD- or CR/CRhMRD-).
Lasso di tempo: 48 months
|
extension phase |
48 months
|
|
Morphologic leukemia-free state (MLFS) rate, based on ELN2022 recommendations.
Lasso di tempo: 48 months
|
extension phase |
48 months
|
|
Event free survival (EFS).
Lasso di tempo: 48 months
|
extension phase |
48 months
|
|
Relapse-free survival (RFS).
Lasso di tempo: 48 months
|
extension phase |
48 months
|
|
Incidence and severity of adverse events according to CTCAE version 5.0.
Lasso di tempo: 48 months
|
extension phase |
48 months
|
|
Early (30-day and 60-day) mortality (in general, non-leukemic).
Lasso di tempo: 48 months
|
extension phase |
48 months
|
|
Time to next cycle, defined as the time from the start of the cycle until the start of the next cycle.
Lasso di tempo: 48 months
|
extension phase |
48 months
|
|
OS of AZA/VEN/COBI treated patients in comparison with a real-world data cohort treated during the same time period and monitored by the Dutch Cancer registry.
Lasso di tempo: 48 months
|
extension phase |
48 months
|
|
Prognostic/predictive impact of disease-associated genetic changes at diagnosis.
Lasso di tempo: 48 months
|
extension phase |
48 months
|
|
Relapse-associated genetic changes (determined at relapse). The average relative dose intensity will be computed and given by categories. The same will be done for treatment deviation.
Lasso di tempo: 48 months
|
extension phase |
48 months
|
|
Clonal evolution during treatment.
Lasso di tempo: 48 months
|
extension phase |
48 months
|
|
Exposure-response and exposure-toxicity relation of venetoclax in patients with AML.
Lasso di tempo: 48 months
|
extension phase |
48 months
|
|
Cost-savings on venetoclax drug costs.
Lasso di tempo: 48 months
|
extension phase |
48 months
|
|
Adherence to venetoclax and cobicistat.
Lasso di tempo: 48 months
|
extension phase |
48 months
|
Collaboratori e investigatori
Sponsor
Sponsor
Pubblicazioni e link utili
Collegamenti utili
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
- Neoplasie
- Neoplasie per tipo istologico
- Malattie ematologiche
- Leucemia, mieloide
- Leucemia
- Malattie emiche e linfatiche
- Leucemia, mieloide, acuta
- Composti di zolfo
- Prodotti chimici organici
- Composti eterociclici, 1-anello
- Composti eterociclici
- Tiazoli
- Azoli
- Acidi nucleici, nucleotidi e nucleosidi
- Acidi, aciclici
- Acidi carbossilici
- Citidina
- Nucleosidi di pirimidina
- Pirimidine
- Composti aza
- Nucleosidi
- Ribonucleosidi
- Carbamati
- Cobicistat
- Azacitidina
- Venetoclax
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- HO171
- 2023 (Sovvenzione/contratto NIH degli Stati Uniti)
- 2023-505379-61-00 (Ctis)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
prodotto fabbricato ed esportato dagli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .